NOVN.CH

102.06

-0.06%↓

LONN.CH

567

-0.18%↓

BANB.CH

62.05

-1.66%↓

NOVN.CH

102.06

-0.06%↓

LONN.CH

567

-0.18%↓

BANB.CH

62.05

-1.66%↓

NOVN.CH

102.06

-0.06%↓

LONN.CH

567

-0.18%↓

BANB.CH

62.05

-1.66%↓

NOVN.CH

102.06

-0.06%↓

LONN.CH

567

-0.18%↓

BANB.CH

62.05

-1.66%↓

NOVN.CH

102.06

-0.06%↓

LONN.CH

567

-0.18%↓

BANB.CH

62.05

-1.66%↓

Kodu・Aktsiate loetelu・Roche Holding AG

Roche Holding AG

Suletud

SektorTervishoid

284.8 0.07

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

283.2

Max

285.6

Põhinäitajad
By Trading Economics
Sissetulek	5.8B 7.8B
Müük	297M 31B
P/E Sektori keskmine	23.37 35.733
Dividenditootlus	3.54
Kasumimarginaal	25.31
Töötajad	103,249
EBITDA	6B

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	3.54% 3.13%

Turustatistika
By TradingEconomics
Turukapital	3.1B 209B
Eelmine avamishind	284.73
Eelmine sulgemishind	284.8

Uudiste sentiment

By Acuity

20%

80%

47 / 371 Pingereas Healthcare

Roche Holding AG Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. juuli 2025, 15:09 UTC

Tulu

Roche Weighs Selling Drugs Directly to Patients in Bid to Lower U.S. Prices -- Update

24. juuli 2025, 05:36 UTC

Tulu

Roche Backs 2025 Views After Strong Sales of Key Drugs

11. juuni 2025, 08:25 UTC

Omandamised, ülevõtmised, äriostud

EQT, Sanofi Co-Led $135 Million Funding Round for Spanish Biotech Company SpliceBio

12. mai 2025, 02:16 UTC

Suurimad hinnamuutused turgudel

Asia Pharma Stocks Fall After Trump's Plan to Cut Drug Costs

24. apr 2025, 07:30 UTC

Tulu

Roche Sales Gain on Boost From Key Drugs Amid U.S. Production Push -- Update

24. apr 2025, 05:31 UTC

Tulu

Roche Sales Rise Boosted By Key Drugs

8. aug 2025, 10:51 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Novartis's Midterm Prospects Look Better Than Roche's -- Market Talk

8. aug 2025, 07:39 UTC

Market Talk

Tulu

Roche Could Reach Peak Earnings Growth This Year -- Market Talk

5. aug 2025, 10:40 UTC

Market Talk

Roche, Novartis Face Limited Tariff Headwinds for Now -- Market Talk

24. juuli 2025, 06:52 UTC

Market Talk

Tulu

Roche Looks Confident in a Tricky Environment -- Market Talk

24. juuli 2025, 05:05 UTC

Tulu

Roche Backs 2025 View

24. juuli 2025, 05:05 UTC

Tulu

Correct: Roche 1H Diagnostics Sales Down 3%, Reported

24. juuli 2025, 05:04 UTC

Tulu

Correct: Roche 1H Sales Rose 4% On Year , Reported

24. juuli 2025, 05:04 UTC

Tulu

Roche 1H Net Pft Was Seen at CHF8.4B

24. juuli 2025, 05:04 UTC

Tulu

Roche 1H Net Pft CHF7.8B

24. juuli 2025, 05:03 UTC

Tulu

Roche 1H Oper Pft CHF12.0B

24. juuli 2025, 05:03 UTC

Tulu

Roche 1H Diagnostics Sales Down 3% at Constant Currency

24. juuli 2025, 05:03 UTC

Tulu

Roche 1H Sales Rose 4% On Year at Constant Currency

24. juuli 2025, 05:02 UTC

Tulu

Roche 1H Sales CHF30.9B , In Line With Analyst Views

21. juuli 2025, 06:44 UTC

Market Talk

Roche Drug Candidate Disappoints in Lung Disease Trials -- Market Talk

16. juuni 2025, 08:55 UTC

Kuumad aktsiad

Stocks to Watch: Victoria's Secret, Renault, U.S. Steel, Sarepta -- WSJ

3. juuni 2025, 07:51 UTC

Market Talk

Roche Unlikely to Get Revenue Boost From Tecentriq Combination With Lurbinectedin -- Market Talk

21. mai 2025, 07:20 UTC

Market Talk

Roche Lymphoma Drug Columvi Dealt Setback by FDA Committee -- Market Talk

2. mai 2025, 06:25 UTC

Market Talk

Tulu

Roche Shows Pipeline Progress But Near-Term Risks Remain -- Market Talk

24. apr 2025, 09:39 UTC

Market Talk

Tulu

Roche's Pipeline in Focus After Solid Results -- Market Talk

24. apr 2025, 09:24 UTC

Market Talk

Tulu

Roche's Reiterated Outlook Looks Reassuring -- Market Talk

24. apr 2025, 09:18 UTC

Market Talk

Tulu

Roche's Results Are Solid -- Market Talk

24. apr 2025, 05:16 UTC

Peamised uudised

Roche Sales Rise, Boosted By Key Drugs

22. apr 2025, 10:51 UTC

Peamised uudised

Drug Companies Step Up 'Make in America' Plans to Counter Tariffs -- WSJ

15. apr 2025, 09:55 UTC

Market Talk

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Roche Holding AG Prognoos

Sentiment

By Acuity

47 / 371 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.